65,437 trials
Heart Failure · Chronic Kidney Disease
Primary: Percent Change From Baseline in Urinary Albumin to Creatinine Ratio (UACR) at Week 12 — -56.391; -42.085; -58.047; -45.01 Percent change from baseline — p=0.3645
Diabetes · SGLT-2i and GLP-1RA Therapies · Diffusion of Responsibility
Primary: Number of Participants With Prescriptions for SGLT-2i or GLP-1RA Medications Among Eligible Patients in Each Arm — 109; 92; 92 Participants
Autosomal Dominant Hypocalcemia (ADH) · Autosomal Dominant Hypocalcemia Type 1 (ADH1)
Primary: Periods 1, 2 and 3: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 5; 13 Participants
Allergic Rhinitis · Conjunctivitis
Primary: Mean Total Nasal Symptom Score (TNSS) (2 to 6 Hours) During Out-of-season Birch Allergen Environmental Exposure Unit (EEU) Challenge (REGN5713-5714-5715 vs. Placebo) at…
Cardiac Surgery · Opioid Use, Unspecified
Primary: Total Opioid Consumption 72 Hours Post-operatively — 165.00; 205.05 morphine milligram equivalents
Bronchiectasis
Primary: The Ability of the Breath Test Model to Distinguish Bronchiectasis From Healthy People — 65; 67; 23 Participants — p=<0.05
Metabolic Syndrome
Primary: SASI Acceptability Questionnaire Score at Pre-Intervention — 3.91 score on a scale
Low Vision · Age Related Macular Degeneration
Primary: Tilt of the PCIOL and IOPCL MAG Complex — 9; 9 Eyes
Obesity · Overweight
Primary: Mean Weight Change in Kg — -2.51; -0.79 kilograms (kg) — p=0.050
Clear Cell Renal Cell Carcinoma · Metastatic Kidney Carcinoma · Stage III Renal Cell Cancer AJCC v7
Primary: Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) — 4; 10; 3; 13 participants
Physical Inactivity · Health Behavior · Healthy Lifestyle
Primary: Steps/Day — 4048.4; 1074.4; 1645.8; 1749.1 Steps/day
Hearing Impairment
Primary: Speech Recognition — 70.03; 67.92; 30.43; 62.71 percentage of words repeated correctly
Healthy
Primary: Button Press Reaction Time — 1.86; 1.53; 1.29 Seconds — p=<.001
Arginase I Deficiency · Hyperargininemia
Primary: Change From Baseline in Plasma Arginine Concentration After 24 Weeks of Treatment — 0.244; 0.918 micromolar — p=<0.0001
Head and Neck Cancer · Lymphedema · Fibrosis
Primary: Total Severity of External Lymphedema and Fibrosis (LEF) — 5.42; 4.08; 3.22; 4.62 score on a scale